Mission and Milestones

Mission: To develop and commercialize new, more effective therapeutics for serious or life-threatening infectious diseases.

Date	Event
2009	SQ109 Phase Ib clinical trial initiated Awarded ARRA stimulus grant for finalization of manufacturing process for SQ109 Awarded grant from NIH for investigation of SQ641 in NonTB indications Raised $4.0M from equity sales in private placement financing
2008	Awarded $2.3M Grant from NIH for development of lead capuramycin drug candidate, SQ641 Raised $2.5M from equity sales in private placement financing
2007	FDA grants Fast-Track designation to SQ109 SQ109 Phase Ia clinical trial completed SQ109 receives European Union Orphan Product designation TB STAT-PAK, a rapid lateral-flow serological test for TB for veterinary applications that Sequella licensed to Chembio Diagnostic Systems, is approved for marketing U.S. Orphan Drug Status Granted for SQ-109 European Medicines Agency (EMEA) Orphan Drug Status granted for SQ-109 Selected to Present at BIO 2007 Total Institutional and other investments including Maryland Department of Econmomic Development total $7.0M
2006	Hires VP of Finance, Marty Zug, MBA Hires Chief Medical Officer, Gary Horwith, M.D. NIH grants exclusive world-wide commercialization license to SQ109 and related compounds Raises $4.1 million from equity sales in private placement financing Files first Investigational New Drug (IND) application with U.S. FDA for new diamine antibiotic SQ109
2005	Receives U.S. patent for TB Patch Diagnostic, and also granted nine ex-US country Patch patents Receives U.S. patent for Therapeutic Diamine Anti-Infective Compounds(SQ109) Raises $2.5 million in equity sales in private placement financing Licenses out veterinary TB diagnostic to ChemBio, Inc.
2004	Sankyo Co., Ltd. grants exclusive worldwide license to commercialize new antibiotics Initiation of clinical trials in South Africa for Patch diagnostic using recombinant protein
2003	Receives first (of 4) NIH Small Business Innovation Research Phase II grant ($1.0 million) Receives first NIH U01 Biodefense Research grant ($1.6 million) Hires EVP Business Development, Alan Klein, MBA
2001	Receive support from NCI/NIAID for development of novel second-generation drugs for Tuberculosis
2000	Awarded $1.2 million NIH Challenge Grant for discovery of new TB drugs Japan BCG Laboratory grants exclusive world-wide license (excl. Japan) to diagnostic Patch Test for Active TB Raises $400,000 in equity sales in private placement financing
1999	Carol A. Nacy, Ph.D., named CEO - Awarded first NIH Small Business Innovation Research Phase I grant Signed CRADA with NIH to discover new TB drugs
1998	Hires first employee, Leo Einck, Ph.D., President - First Angel financing ($960,000)
1997	Incorporation in Delaware First sale of common stock, Founders ($560,000)